Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, S. Fagiuoli, Marcello Persico et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 19
Virological patterns of HCV patients with failure to interferon‐free regimensMario Starace, Carmine Minichini, Stefania De Pascalis et al.|Journal of Medical Virology|2018Cited by 16
ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free RegimensNicola Coppola, Ivan Gentile, Stefania De Pascalis et al.|Antiviral Therapy|2016Cited by 13
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosisAntonio Ascione, N. Caporaso, M. De Luca et al.|Infection|2018Cited by 8
DAA-Based Treatment for HIV–HCV-Coinfected Patients: Analysis of Factors of Sustained Virological Response in a Real-Life StudyLoredana Alessio, Nicola Coppola, Lorenzo Onorato et al.|Antiviral Therapy|2019Cited by 7